Dashboard
Manage Tickers

GMABGENMAB A/S

Nasdaq genmab.com


$ 25.14 $ 0.25 (1 %)    

Wednesday, 03-Jul-2024 12:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 490.95 $ 4.06 (0.83 %)
DIA $ 392.84 $ -0.46 (-0.12 %)
SPY $ 551.46 $ 2.45 (0.45 %)
TLT $ 91.86 $ 1.19 (1.31 %)
GLD $ 217.99 $ 2.43 (1.13 %)
$ 25.15
$ 25.11
$ 0.00 x 0
$ 0.00 x 0
$ 25.11 - $ 25.26
$ 24.53 - $ 42.72
236,621
na
113.18M
$ 0.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

reported-earlier-genmabs-epcoritamab-receives-ema-opinion-for-follicular-lymphoma-treatment
Reported Earlier, Genmab's Epcoritamab Rec...
06/28/2024 07:36:11

Genmab A/S (NASDAQ:GMAB) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Hu...

abbviegenmabs-epkinly-fda-approval-is-a-positive-step-analyst-says-additional-expansion-opportunities-underway
AbbVie/Genmab's Epkinly FDA Approval Is A ...
06/27/2024 17:22:09

The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractor...

btig-maintains-buy-on-genmab-raises-price-target-to-47
BTIG Maintains Buy on Genmab, Raises Price...
06/27/2024 12:01:28

BTIG analyst Kaveri Pohlman maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $46 to $47.

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
06/27/2024 10:31:03

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

genmab-announced-that-the-us-fda-approved-epkinly-for-the-treatment-of-adults-with-relapsed-or-refractory-follicular-lymphoma-after-two-or-more-lines-of-systemic-therapy
Genmab Announced That The U.S. FDA Approve...
06/27/2024 06:54:13

10-analysts-assess-genmab-what-you-need-to-know
10 Analysts Assess Genmab: What You Need T...
06/20/2024 12:00:25

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
06/20/2024 10:43:20

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

truist-securities-maintains-buy-on-genmab-raises-price-target-to-53
Truist Securities Maintains Buy on Genmab,...
06/04/2024 12:54:42

Truist Securities analyst Asthika Goonewardene maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $5...

genmabs-phase-2-trial-shows-tisotumab-vedotin-achieves-325-objective-response-rate-in-head-and-neck-cancer
Genmab's Phase 2 Trial Shows Tisotumab Ved...
06/03/2024 13:11:09

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
06/03/2024 10:34:22

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

reported-earlier-genmabs-epcoritamab-shows-95-response-rate-in-untreated-follicular-lymphoma-patients-in-preliminary-epcore-nhl-2-study-results
Reported Earlier, Genmab's Epcoritamab Sho...
06/03/2024 06:28:05

Preliminary analysis of data from the EPCORE™ NHL-2 study demonstrates patients with previously untreated follicular lymphoma...

Core News & Articles
Genmab, BioNTech Announced Data At ASCO, S...
06/02/2024 15:02:07

Genmab A/S (NASDAQ:GMAB) and BioNTech SE (NASDAQ:BNTX) todayannounced initial data from the Phase 2 GCT1046-04 trial (NCT051172...

intuit-workday-and-other-big-stocks-moving-lower-in-fridays-pre-market-session
Intuit, Workday And Other Big Stocks Movin...
05/24/2024 09:45:52

what-9-analyst-ratings-have-to-say-about-genmab
What 9 Analyst Ratings Have To Say About G...
05/20/2024 15:00:19

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
05/20/2024 10:26:42

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

genmab-announces-presentation-of-multiple-abstracts-on-epcoritamab-at-2024-european-hematology-association-congress-on-june-13-16
Genmab Announces Presentation Of Multiple ...
05/14/2024 14:10:14

genmab-announces-presentation-of-multiple-abstracts-on-epcoritamab-at-2024-european-hematology-association-congress-on-june-13-16-2024
Genmab Announces Presentation Of Multiple ...
05/14/2024 14:09:41

Core News & Articles
Watching Genmab; Shares Trading Higher Aft...
05/13/2024 16:00:50

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
05/03/2024 19:59:17

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

genmab-q1-2024-revenue-60425m
Genmab Q1 2024 Revenue $604.25M
05/02/2024 15:05:48

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)